BiotechTube

pembrolizumab + brentuximab vedotin

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hodgkin Lymphoma

Conditions

Hodgkin Lymphoma

Trial Timeline

May 23, 2016 → Jan 14, 2026

NCT ID
NCT02684292

About pembrolizumab + brentuximab vedotin

pembrolizumab + brentuximab vedotin is a phase 3 stage product being developed by Merck for Hodgkin Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02684292. Target conditions include Hodgkin Lymphoma.

What happened to similar drugs?

1 of 20 similar drugs in Hodgkin Lymphoma were approved

Approved (1) Terminated (2) Active (17)
❌Nivolumab + Brentuximab vedotinOno PharmaceuticalPhase 3
🔄R-mabHDI and ABVD + ABVDEli LillyPhase 3
🔄enzastaurin + placeboEli LillyPhase 3
🔄Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3
🔄Camrelizumab + Investigator's choice of ChemotherapyJiangsu Hengrui MedicinePhase 3
🔄Zoledronic Acid + Vitamin D + Calcium CarbonateNovartisPhase 3
❌Ofatumumab + Rituximab + Ofatumumab + RituximabNovartisPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02684292Phase 3Completed

Competing Products

20 competing products in Hodgkin Lymphoma

See all competitors
ProductCompanyStageHype Score
AFM13AffimedPhase 2
25
VIP152 + BTKiVincerx PharmaPhase 1
11
PLX3397Daiichi SankyoPhase 2
35
YM155 + RituximabAstellas PharmaPhase 2
35
TazemetostatEisaiPhase 2
35
ONTAKEisaiPhase 2
35
TazemetostatEisaiPhase 1
29
ME-401Kyowa KirinPhase 1
29
ME-401Kyowa KirinPhase 2
39
TirabrutinibOno PharmaceuticalPhase 1
29
ONO-7018Ono PharmaceuticalPhase 1
33
Nivolumab + Brentuximab vedotinOno PharmaceuticalPhase 3
32
ONO-7018 + ONO-7018Ono PharmaceuticalPhase 1
33
R-mabHDI and ABVD + ABVDEli LillyPhase 3
36
Prednisone + Vinblastine + Doxorubicin (Adriamycin) + GemcitabineEli LillyPhase 1/2
32
gemcitabineEli LillyPhase 2
27
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
35
LY4152199 - IVEli LillyPhase 1
36
R-mabHD + ABVDEli LillyPhase 2
31
enzastaurin + placeboEli LillyPhase 3
40